SLC5A2 and type 2 diabetes mellitus: Qiu et al. (1) implemented a meta-analysis based on nine cohort studies directly comparing cardiovascular and renal endpoints between sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP1RAs) in patients with type 2 diabetes (T2D).